@ARTICLE{
author={Weiss Jared,Goldschmidt Jerome,Andric Zoran G,Dragnev Konstantin H,Gwaltney Chad,Skaltsa Konstantina,Pritchett Yili,Antal Joyce M,Morris Shannon R,Daniel Davey},
year={2021},
title={Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies},
journal={CLINICAL LUNG CANCER},
volume={22},
number={5},
pages={449-460},
document_type={Article},
} 

@ARTICLE{
author={Hart Lowell L,Ferrarotto Renata,Andric Zoran G,Beck Thaddeus J,Subramanian Janakiraman,Radosavljevic Davorin Z,Zaric Bojan,Hanna Wahid T,Aljumaily Raid,Owonikoko Taofeek K,Verhoeven Didier,Xiao Jie,Morris Shannon R,Antal Joyce M,Hussein Maen A},
year={2021},
title={Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study},
journal={ADVANCES IN THERAPY},
volume={38},
number={1},
pages={350-365},
document_type={Article},
}